Table of Contents

01 NICE's response to comments on the Appraisal Consultation Document (ACD2)
02. Consultee and commentator comments on the ACD from British Association for the Study of the Liver
03. Consultee and commentator comments on the ACD from British Liver
04 Consultee and commentator comments on the ACD from Liver4Life
05 Company response to ACD2 consultation
06 Company Clarification on Factual Inaccuracies in ACD2
07 Company Clarification of factual inaccuracies in the Evidence Review Group critique of the addendum
08. Consultee and commentator comments on the ACD from Royal College of Nursing
09 Clinical expert comments on the ACD - Sharcross
10 Public comments on the ACD2 received via the NICE website
11 Additional evidence submitted by the company, Norgine, in December 2013
12 Supplementary Analyses Suggested in the ERG Critique of Norgine Addendum
13 Review of Additional Evidence prepared by PenTAG
14 Exploratory analyses prepared by PenTAG
15 Additional evidence submitted by the company, Norgine, in November 2014
16 Norgine response to ERG queries on the additional evidence
17 ERG critique of the additional evidence, prepared by Southampton Health Technology Assessment Centre